Business Wire

Alpha’s latest report explores the impact of retail investors on fund finance provision

17.9.2025 11:00:00 CEST | Business Wire | Press Release

Share

Alpha Group International plc (LON:ALPH) today announced the launch of its latest Lender Book Report, exploring and analysing the latest fund finance market trends.

What does retail investment mean for subscription lines?

Private capital funds, once the reserve of institutions such as pension funds and sovereign wealth funds, are rapidly opening up to a wider base of potential investors. Indeed, last month saw President Trump issue an executive order calling for expanded access to private equity and other alternative investments for 401(k) plans and their participants.

While the push to open up private capital markets will undoubtedly see an influx of capital coming from new investor types, it also throws up a whole host of ramifications that need to be addressed.

One of which is the impact on fund financing, namely subscription line loans. Traditionally, these facilities are secured against capital commitments from institutional investors into an alternative asset manager’s closed-ended fund. Will lenders be willing, or able, to extend subscription lines against non-institutional commitments?

Key finding

Drawing detailed data from its proprietary fund finance database – Alpha Match – which includes more than 400 fund finance lender profiles and more than 130 data points per lender, combined with insights from the fund finance deal team, which has advised on over 85 transactions, this latest report offers a uniquely comprehensive perspective on this mega-trend.

The latest Lender Book Report found clear differences in subscription line lender appetites when it comes to non-institutional investors, depending on where the lender is based, and the type of lending organisation. The data revealed:

  • US lenders showed greater willingness to accept non-institutional investors compared with their more conservative European counterparts.
  • Additionally, non-bank lenders demonstrated higher flexibility when it comes to non-institutional LPs compared with traditional banks.

Other key findings from the report

In this latest Lender Book Report, Alpha’s Fund Finance team also explored key market trends impacting NAV facilities and GP financing, asking the data what is really happening. The report reveals how private capital funds are responding to this change in supply of NAV financing. It also reveals a mismatch between supply and demand of GP financing, highlighting an urgent need to innovate solutions.

Background to the report: A lack of publicly available data

The fund finance market, despite being estimated to be worth more than $1trn and fast-evolving into an asset class of its own – suffers from a lack of available transaction data and transparency. Most of what we know about this market is based on anecdotal evidence and surveys of small sample groups.

It is against this backdrop that Alpha, using data from its proprietary fund finance database, delivers an independent, data-driven analysis of the subscription line, NAV facility, and GP financing markets.

Click here to request the full report

View source version on businesswire.com: https://www.businesswire.com/news/home/20250917980663/en/

Contacts

To find out more about Alpha Match, visit www.alphagroup.com/match -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.alphagroup.
com%2Fmatch&esheet=54323955&newsitemid=20250917980663&lan=en-US&anchor=www.alpha
group.com%2Fmatch&index=2&md5=feac5a3e6a203070615b41b884cfdd48 or email
match@alphagroup.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye